# US 2013/0156842 A1 · Bioadhesive drug formulations for oral transmucosal delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156842 A1
- Document ID: US20130156842A1
- Status: Published application
- Kind: A1
- Application number: 13/595,879
- Filed: 2012-08-27
- Published: 2013-06-20
- Earliest claimed: 2006-01-06
- Assignees: AcelRx Pharmaceuticals, Inc.
- Inventors: Stelios Tzannis; Larry Hamel; Pamela Palmer; Thomas Schreck; Andrew I. Poutiatine
- Web page: https://patentgrep.com/patent/US20130156842A1

## CPC

- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61J 7/00: Devices for administering medicines orally, e.g. spoons (calibrated capacity measures for fluids or fluent solid material G01F19/00; weighing spoons G01G19/56); Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J 7/0023: {Spoons}
- A61J 7/0046: {Cups, bottles or bags}
- A61J 7/0053: {Syringes, pipettes or oral dispensers}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61P 25/00: Drugs for disorders of the nervous system
- A61J 3/005: {Coating of tablets or the like (coating of sweetmeats or confectionery A23G3/20; coating of granules in general B01J2/006)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same.

## Claims

### Claim at position 1

1-92. (canceled)

### Claim 93

A method of treating pain in a subject, comprising administering a bioadhesive tablet to the oral mucosa of a subject,
wherein said tablet comprises:
(a) from about 2.5 to about 100 micrograms of sufentanil, expressed as the base; and
(b) a bioadhesive material, wherein said bioadhesive material provides for adherence to the oral mucosa of said subject, and
(c) said tablet has a volume of from about 0.1 microliters to about 50 microliters,
wherein after administration of said tablet to said subject, said tablet provides a minimal saliva response and minimal swallowing of sufentanil; and more than 50% of drug delivery of sufentanil occurs via the oral transmucosal route.

### Claim 94 (depends on 93)

The method according to claim 93, wherein said tablet forms a hydrogel upon contact with an aqueous fluid.

### Claim 95 (depends on 93)

The method according to claim 93, wherein said tablet is an eroding tablet wherein upon contact with an aqueous fluid, the surface of the tablet hydrates and erodes, without formation of a hydrogel.

### Claim 96 (depends on 93)

The method according to claim 93, wherein upon contact with an aqueous fluid said tablet disintegrates and forms a film.

### Claim 97 (depends on 93)

The method according to claim 93, wherein dissolution of said tablet is independent of pH.

### Claim 98 (depends on 97)

The method according to claim 97, wherein dissolution of said tablet is independent of pH over a pH range of about 4 to 8.

### Claim 99 (depends on 93)

The method according to claim 93, wherein said tablet has a volume of from about 0.5 to about 10.0 microliters.

### Claim 100 (depends on 93)

The method according to claim 93, wherein said tablet has a volume of from about 1.0 to about 25 microliters.

### Claim 101 (depends on 93)

The method according to claim 93, wherein said tablet has a volume of from about 3.0 to about 15.0 microliters.

### Claim 102 (depends on 93)

The method according to claim 93, wherein said tablet comprises 10 micrograms of sufentanil, expressed as the base.

### Claim 103 (depends on 93)

The method according to claim 93, wherein said tablet comprises 15 micrograms of sufentanil, expressed as the base.

### Claim 104 (depends on 93)

The method according to claim 93, wherein said tablet has a thickness of from 0.5 to 3.0 mm.

### Claim 105 (depends on 93)

The method according to claim 93, wherein said tablet disintegrates over a period of 10-30 minutes following sublingual administration to said subject.

### Claim 106 (depends on 93)

The method according to claim 93, wherein a single or repeated oral transmucosal administration to a subject results in a bioavailability of greater than 70%.

### Claim 107 (depends on 93)

The method according to claim 93, wherein following administration, said tablet adheres to the oral mucosa of said subject throughout the period of drug delivery.

### Claim 108 (depends on 93)

The method according to claim 93, wherein said tablet exhibits an attachment force of from 0.03 to 0.18 N/cm2 to a porcine mucosa substrate in vitro.

### Claim 109 (depends on 93)

The method according to claim 93, wherein the amount of the drug in said formulation absorbed via the oral mucosa is selected from the group consisting of at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% and at least 99% of the drug in said bioadhesive tablet.

### Claim 110 (depends on 109)

The method according to claim 109, wherein at least 55% of the total amount of drug in said formulation is absorbed via the oral transmucosal route.

### Claim 111 (depends on 109)

The method according to claim 109, wherein at least 60% of the total amount of drug in said formulation is absorbed via the oral transmucosal route.

### Claim 112 (depends on 93)

The method according to claim 93, wherein said tablet is administered using a single dose applicator (SDA).

### Claim 113 (depends on 112)

The method according to claim 112, wherein said SDA is effective to accurately place said tablet in the sublingual space.

### Claim 114 (depends on 113)

The method according to claim 113, wherein said tablet remains dry in said SDA prior to dispensing, at which point a single tablet is dispensed from the SDA into the mouth of said subject.

### Claim 115 (depends on 1)

The method according to claim 1, wherein said tablet is administered using a drug dispensing device, wherein said drug dispensing device is effective to check user identification and provide a lockout period between dose dispenses.

### Claim 116 (depends on 115)

The method according to claim 115, wherein said drug dispensing device is effective to accurately place said tablet in the sublingual area.

### Claim 117 (depends on 116)

The method according to claim 116, wherein said tablet remains dry in the drug dispensing device prior to dispensing, at which point a single tablet is dispensed from the drug dispensing device into the mouth of said subject.

### Claim 118 (depends on 116)

The method according to claim 116, wherein said drug dispensing device further comprises a user interface wherein dosage history can be transferred to another device, computer or network.
